公开(公告)号：WO2011001276A1

公开(公告)日：2011-01-06

申请号：PCT/IB2010/001629

申请日：2010-06-25

Applicant: PHILOGEN S.P.A. ,  MANUELA, Kaspar ,  TRACHSEL, Eveline

Inventor： MANUELA, Kaspar ,  TRACHSEL, Eveline

IPC: A61K39/395 ,  A61K47/48

CPC classification number: A61K39/39558 ,  A61K38/2013 ,  A61K47/48584 ,  A61K47/48623 ,  A61K47/6813 ,  A61K47/6843 ,  A61K47/6855 ,  A61K47/6865 ,  A61K2039/507 ,  C07K14/7155 ,  C07K16/28 ,  C07K16/32 ,  C07K2319/00 ,  A61K2300/00

Abstract: This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.

Abstract translation: 本发明涉及使用抗ErbB抗体（例如西妥昔单抗或曲妥珠单抗）与靶向腱生蛋白-C的抗体 - 白细胞介素2（IL2）缀合物的组合治疗癌症。

公开(公告)号：WO2011072240A1

公开(公告)日：2011-06-16

申请号：PCT/US2010/059919

申请日：2010-12-10

Applicant: CEDARS-SINAI MEDICAL CENTER ,  PATIL, Rameshwar ,  HOLLER, Eggehard ,  BLACK, Keith L. ,  LJUBIMOVA, Julia, Y.

Inventor： PATIL, Rameshwar ,  HOLLER, Eggehard ,  BLACK, Keith L. ,  LJUBIMOVA, Julia, Y.

IPC: A01N43/52 ,  A61K31/425

CPC classification number: A61K47/593 ,  A61K31/4188 ,  A61K31/425 ,  A61K47/48061 ,  A61K47/48215 ,  A61K47/48246 ,  A61K47/48338 ,  A61K47/48384 ,  A61K47/48561 ,  A61K47/48584 ,  A61K47/48623 ,  A61K47/48669 ,  A61K47/48692 ,  A61K47/545 ,  A61K47/60 ,  A61K47/64 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6865 ,  A61K47/6877 ,  A61K47/6883 ,  A61K47/6889 ,  A61K47/6898 ,  C07K16/2881 ,  C07K16/3015 ,  C07K16/3053 ,  C07K2317/24 ,  C07K2317/77

Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.

Abstract translation: 本发明涉及用于治疗诸如癌症的疾病或疾病的药物递送方法。 在一个实施方案中，本发明提供了通过将其酰肼形式的TMZ与聚马来酸平台结合来制备替莫唑胺（TMZ）的多功能纳米缀合物的方法。 在另一个实施方案中，聚马来酸平台与转铁蛋白受体的单克隆抗体，三聚亮氨酸（LLL）部分和/或聚乙二醇（PEG）部分缀合。 本发明涉及用于治疗诸如癌症的疾病或疾病的药物递送方法。 在一个实施方案中，本发明提供了通过将其酰肼形式的TMZ与聚马来酸平台结合来制备替莫唑胺（TMZ）的多功能纳米缀合物的方法。 在另一个实施方案中，聚马来酸平台与转铁蛋白受体的单克隆抗体，三聚亮氨酸（LLL）部分和/或聚乙二醇（PEG）部分缀合。

公开(公告)号：WO2017139623A1

公开(公告)日：2017-08-17

申请号：PCT/US2017/017435

申请日：2017-02-10

Applicant: IMMUNOMEDICS, INC.

Inventor： CHANG, Chien-Hsing ,  GOLDENBERG, David M.

IPC: A61K45/06 ,  A61K47/48 ,  C07K16/30

CPC classification number: C07K16/3061 ,  A61K31/4535 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/4985 ,  A61K39/3955 ,  A61K41/0038 ,  A61K45/06 ,  A61K47/48384 ,  A61K47/48569 ,  A61K47/48584 ,  A61K47/48592 ,  A61K47/486 ,  A61K47/48607 ,  A61K47/48615 ,  A61K47/48623 ,  A61K47/4863 ,  A61K47/48638 ,  A61K47/48684 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  A61K51/1057 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/3092 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.

Abstract translation: 本发明涉及包含附着于抗癌抗体或抗原结合抗体片段的药物的治疗性ADC。 优选药物是SN-38。 更优选地，抗体或其片段结合Trop-2并且该疗法用于治疗Trop-2阳性癌症。 最优选地，抗体是hRS7。 将ADC施用给患有癌症的受试者并结合ABCG2抑制剂。 联合治疗有效治疗单独对抗药物和/或单独对ADC有抗性的癌症。

公开(公告)号：WO2015191610A3

公开(公告)日：2016-02-04

申请号：PCT/US2015034941

申请日：2015-06-09

Applicant: BIOMED VALLEY DISCOVERIES INC ,  US HEALTH

Inventor： SAHA SAURABH ,  ZHANG XIAOYAN M ,  DIMITROV DIMITER ,  ZHU ZHONGYU ,  ST CROIX BRAD ,  ZUDAIRE ENRIQUE

IPC: A61P35/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K47/48569 ,  A61K31/4745 ,  A61K39/39558 ,  A61K47/48623 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6865 ,  A61K47/6869 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a molecularly targeted agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.

Abstract translation: 本发明尤其提供了在受试者中治疗或改善疾病如癌症的作用的方法。 所述方法包括：向有需要的受试者施用（a）治疗有效量的分子靶向药剂; 和（b）治疗有效量的单克隆抗体或其抗原结合片段，其中所述单克隆抗体含有：（i）重链可变区（VH），其包含选自SEQ ID NO：1， SEQ ID NO：3，SEQ ID NO：5和SEQ ID NO：7; 和（ii）轻链可变区（VL），其包含选自SEQ ID NO：2，SEQ ID NO：4，SEQ ID NO：6和SEQ ID NO：8的氨基酸序列。 本文还提供了组合物，包括药物组合物和用于治疗疾病如癌症的试剂盒。

公开(公告)号：WO2011053901A2

公开(公告)日：2011-05-05

申请号：PCT/US2010054939

申请日：2010-11-01

Applicant: UNIV NORTHWESTERN ,  DRAVID VINAYAK P ,  SHARMA SAURABH ,  TOMITA TADANORI ,  VIOLA KIRSTEN L ,  KLEIN WILLIAM L

Inventor： DRAVID VINAYAK P ,  SHARMA SAURABH ,  TOMITA TADANORI ,  VIOLA KIRSTEN L ,  KLEIN WILLIAM L

IPC: G01N33/53 ,  A61K49/16 ,  G01N27/72 ,  G01N33/574

CPC classification number: A61K47/6923 ,  A61K41/0052 ,  A61K47/48623 ,  A61K47/6865 ,  A61K49/1833 ,  A61K49/186 ,  A61K49/1875 ,  A61N2/004 ,  B82Y5/00

Abstract: The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use as targeted therapeutic agents for cancers (e.g., medulloblastoma) and Alzheimer's disease and related diseases and conditions.

Abstract translation: 本发明涉及作为诊断剂的磁性纳米结构，其提供了作为诊断剂和治疗剂的双重功能。 具体而言，本发明涉及包含磁性纳米结构的组合物及其作为癌症（例如成神经管细胞瘤）和阿尔茨海默氏病及相关疾病和病症的靶向治疗剂的用途。

公开(公告)号：WO2009100194A2

公开(公告)日：2009-08-13

申请号：PCT/US2009033182

申请日：2009-02-05

Applicant: IMMUNOMEDICS INC ,  GOVINDAN SERENGULAM V ,  GOLDENBERG DAVID M ,  MOON SUNG-JU

Inventor： GOVINDAN SERENGULAM V ,  GOLDENBERG DAVID M ,  MOON SUNG-JU

IPC: C07K16/00 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00

CPC classification number: A61K45/06 ,  A61K47/48215 ,  A61K47/48384 ,  A61K47/48523 ,  A61K47/4853 ,  A61K47/48561 ,  A61K47/48569 ,  A61K47/48584 ,  A61K47/48592 ,  A61K47/486 ,  A61K47/48607 ,  A61K47/48615 ,  A61K47/48623 ,  A61K47/4863 ,  A61K47/48638 ,  A61K47/48715 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6839 ,  A61K47/6841 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6861 ,  A61K47/6863 ,  A61K47/6865 ,  A61K47/6867 ,  A61K47/6869 ,  A61K47/6889 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/73

Abstract: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.

Abstract translation: 本发明涉及具有改善的靶向各种患有靶向部分（例如抗体或抗体片段），接头和喜树碱作为治疗部分的病变细胞的能力的治疗性缀合物，还涉及制备和使用所述缀合物的方法 。

公开(公告)号：WO2003100033A2

公开(公告)日：2003-12-04

申请号：PCT/US2003/008048

申请日：2003-03-13

Applicant: BIOGEN, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  VIOLETTE, Shelia, M. ,  WEINREB, Paul, H. ,  SIMON, Kenneth, J. ,  SHEPPARD, Dean ,  LEONE, Diane, R.

Inventor： VIOLETTE, Shelia, M. ,  WEINREB, Paul, H. ,  SIMON, Kenneth, J. ,  SHEPPARD, Dean ,  LEONE, Diane, R.

IPC: C12N

CPC classification number: C07K16/2839 ,  A61K47/48507 ,  A61K47/48561 ,  A61K47/48623 ,  A61K47/68 ,  A61K47/6835 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6865 ,  A61K51/1027 ,  A61K51/1066 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57492 ,  G01N33/6893 ,  G01N2333/70546 ,  G01N2800/085 ,  G01N2800/205

Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose %Qmediated diseases.

Abstract translation: 特异性结合M.96的单克隆抗体。 还包括使用这些抗体治疗具有或具有006介导的疾病的风险的哺乳动物或诊断％Q介导的疾病的方法。